amg 509
mAbexperimentalMulti-specific
Clinical trial activity
7 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
2
Phase 3
2
Phase 4
0
Earliest trial started Jan 10, 2020 (NCT04221542)
Timeline
Indications
Mechanism of action
- Metalloreductase STEAP1INHIBITOR
STEAP1 inhibitor
- T-cell surface glycoprotein CD3 epsilon chainImmunity, passive
CD3E immunity, passive
Chemistry & pharmacology
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07297979 | Phase 1 | Jan 16, 2026 | Amgen |
| NCT07213674 | Phase 3 | Nov 1, 2025 | Amgen |
| NCT07140900 | Phase 1 | Oct 7, 2025 | Amgen |
| NCT06691984 | Phase 3 | Jan 31, 2025 | Amgen |
| NCT06613100 | Phase 1 | Oct 31, 2024 | Amgen |
| NCT06555796 | Phase 1 | Sep 23, 2024 | Amgen |
| NCT04221542 | Phase 1 | Jan 10, 2020 | Amgen |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Amgen | For profit | 7 | 7 | 2 | 2020 |
1 organizations
Page 1 / 1